

Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction

Ataollah Ghahiri, Neda Mogharehabed, Naeimehossadat Hosseini¹

Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, ¹Medical Student Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Background: The purpose of this study was to compare the three different strategies, intravenous (IV) hydroxyethyl starch (HES), IV human albumin (HA), and oral Cabergoline (Cb) in the prevention of ovarian hyperstimulation syndrome (OHSS). **Materials and Methods:** In this prospective randomized clinical trial, 91 women at high risk of developing OHSS were allocated into the three groups, group one received 2 vial (2 × 50 ml) IV HAs, in group two, 1000 ml of 6% HES was administered IV, both groups 30 min after oocyte retrieval within 4 h. Group three, 31 infertile patients received oral Cb 0.5 mg daily for 7 days after oocyte retrieval. Patients were visited 14 ± 1 days after *in-vitro* fertilization and if β -human chorionic gonadotropin level >10, transvaginal ultrasonography was performed 2 weeks later to confirm intrauterine pregnancy. Patients were followed up weekly for 3 months for signs of OHSS and were also informed about the signs of OHSS and asked to contact immediately if any symptoms of were detected. **Results:** None of the participants in group HES developed severe OHSS and only 3 patients (10%) developed mild to moderate OHSS. The incident of severe OHSS was significantly higher in albumin group compared to Cb and HES group ($P = 0.033$ and $P < 0.001$, respectively). Also, the probability of developing severe OHSS was higher in Cb group than group HES ($P = 0.031$). **Conclusion:** The findings from this study suggest that administration of 1000 ml of HES 6% has a higher prophylactic effect compared to administration of IV HA and oral Cb.

Key words: Cabergoline, human albumin, hydroxyethyl starch, ovarian hyperstimulation syndrome, ovarian induction

How to cite this article: Ghahiri A, Mogharehabed N, Hosseini N. Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction. *J Res Med Sci* 2015;20:693-6.

INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is of the most serious complications of ovary stimulation^[1] and is classified as mild, moderate, and severe. The incidence rate of mild form of this clinical condition after *in-vitro* fertilization (IVF) is 33% and for moderate and severe form, the incidence rate is 3-6% and 1-3%, respectively.^[2] The corner stone of this syndrome is shifting of fluid from vessels into the intracellular space.^[3,4] Although the underlying pathophysiology still unknown but vascular

endothelial growth factor (VEGF) through interaction with VEGF receptor-2, human chorionic gonadotropin (hCG), and interleukin 6 and interleukin 8 are suggested to be the mediators of vascular permeability.^[5] Fluid therapy, thromboembolic prophylaxis, and ascites control are suggested as possible treatments. Yet, no definite treatment is available for this syndrome, and therefore therapy is supportive and conservative according to the severity of symptoms. Other suggested strategies are cycle cancelation, use of gonadotropin-releasing hormone (GnRH) agonist, coasting, and intravenous (IV) albumin.^[6,7] First introduced by Asch *et al.*,^[8] many randomized clinical trials demonstrated the potential

Access this article online

Quick Response Code:	Website: www.jmsjournal.net
	DOI: ****

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence: Dr. Neda Mogharehabed, Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: nedamogharehabed@gmail.com

Received: 03-07-2014; **Revised:** 26-08-2014; **Accepted:** 26-08-2015

protective role of IV albumin in the prevention of OHSS.^[9-11] However, some studies suggest that human albumin (HA) does not decrease the incidence of OHSS^[12] and that due to possible side effects, HA is not recommended^[13,14] in OHSS prevention. Hydroxylethyl starch (HES), another colloid solution was also suggested as an alternative to HA in the prevention of OHSS. A recent study on 9 RCTs revealed that compared to albumin, HES demonstrated a significant decrease in the incidence of severe OHSS.^[10] The effect of Cabergoline (Cb), a dopamine agonist which dephosphorylates VEGFR-2 and, therefore, inhibits the development of new vessels and vascular hyperpermeability was studied in a few studies. Alvarez *et al.* demonstrated that Cb reduces moderate OHSS in patients undergoing assisted reproduction.^[15] Another randomized clinical trial comparing HA and Cb showed that low dose oral Cb decrease both incidence and severity of OHSS.^[16] Up to now, no study was designed to evaluate the prophylactic effect of these three strategies at a time. The aim of this study is to compare the effect of IV HA, HES, and Cb in preventing OHSS in patients at severe risk of developing severe OHSS, who undergo IVF.

MATERIALS AND METHODS

Patients

This study was designed as a randomized clinical trial to compare the efficacy of the three different strategies Cb, HA, and HES in the prevention of OHSS following IVF. Ninety-one eligible patients referring to Al-Zahra hospital and Isfahan fertility center during July 2012-October 2013 for IVF were enrolled in the study by convenient sampling method. Inclusion criteria were being at high risk of developing OHSS, which was either one of the followings: Estradiol value >3000 pg/ml and/or more than 20 follicles on the day of HCG administration and/ or previous history of OHSS. Written consent was obtained from all the participants. Patients with any history of drug sensitivity or co-morbidity were excluded. The study was approved by Isfahan Ethical Committee of Isfahan University of Medical Sciences (project number: 392298).

Follicle stimulation protocol

All the patients went through a same stimulation protocol. The patients were given oral contraceptive for one cycle. On day 21st of menstrual cycle, GnRH-agonist was started with a daily dose of 1 mg subcutaneously and was continued for 10 days or until bleeding occurs followed by 0.5 mg daily SC until at least two follicles ≥ 17 mm in diameter were detected in transvaginal ultrasound, human menopausal gonadotropin (HMG) 150 IU daily was started on the 3rd day of menstruation for 7-12 days until at least two follicles ≥ 17 mm in diameter were detected in transvaginal ultrasound. Transvaginal ultrasound was conducted every

2 days from 5th day after HMG administration up to detection of favorable follicles mentioned above. After maturation of follicles was confirmed on ultrasonography, GnRH-agonist, and HMG was stopped and hCG, 5000 IU was administered Intramuscularly. Meanwhile, serum estradiol level was measured 5 days after HMG administration and on the day of hCG injection. Vaginal suppository of progesterone 400 μ g daily is started after hCG administration. Patients considered high risk according to the criteria mentioned above were enrolled in the study. Thirty-six hours after administration of hCG, oocyte retrieval was performed through vaginal ultrasound-guided procedure. IVF was performed and fertilized embryos were then transferred into uterus.

Treatment

Ninety-one eligible patients were randomly assigned into three groups using random number table. Group one, consisted of 30 patients, received 2 vial (2×50 ml) HAS (octabin 20%, Octapharma, Switzerland) IV 30 min after oocyte retrieval within 4 h. In group two ($n = 30$), 1000 ml of 6% HES (Voluven, Fresenius Kabi, Germany) was administered IV 30 min after oocyte retrieval within 4 h. Group three, 31 infertile patients were treated with oral Cb (Dostinex, Pfizer, Italy), 0.5 mg daily for 7 days after oocyte retrieval.

Patients were visited 14 ± 1 days after IVF and if β -hCG level >10, transvaginal ultrasonography was performed 2 weeks later to confirm intrauterine pregnancy.

Patients were followed up weekly for 3 months for signs of OHSS and were also informed about the signs of OHSS and asked to contact us immediately if any symptoms of were detected. OHSS was diagnosed according to criteria defined previously by Golan *et al.*^[17] Mild OHSS was defined as abdominal distension and discomfort with or without nausea, vomiting and/or diarrhea, with enlarged ovaries, and moderate OHSS was defined as mild OHSS plus ascites proved by ultrasound, and severe OHSS was present if features of moderate OHSS were present along with ascites and/or hydrothorax and difficulty breathing or all the mentioned criteria with plus change in blood volume, hemoconcentration and increased blood viscosity, coagulation abnormality, and diminished renal perfusion and function.

Statistical analysis

Data were analyzed using SPSS (Version 16, SPSS Inc., Chicago, IL, USA). Results were presented in means \pm standard deviation. Statistical analysis was performed using Chi-square test, and one-way ANOVA when appropriate. The defined level of statistical significance was $P < 0.05$.

RESULTS

In this study, 91 patients were included and divided into three groups of albumin, HES, and Cb each consisted of 30, 30, and 31 subjects, respectively. None of the patients demonstrated adverse reaction due to the administration of HES, Cb or HA.

The mean age of patients was 31.53 ± 3.51 . There was no significant difference between each group regarding gravidity, parity, death, ectopic pregnancy, abortion, and mean age ($P = 0.18, P = 0.13, P = 0.92, P = 0.41, P = 0.25, P = 0.08$, respectively). The baseline characteristics of the patients are demonstrated in Table 1.

Of all the participants in this study, 38 women developed OHSS (41.8%), a most frequently mild form with 28.6%. Eight patients developed moderate (8.8%) and four patients (4.4%) developed severe OHSS.

Table 2 demonstrates the incident OHSS in each group of participants. None of the participants in group HES developed severe OHSS and only 3 patients (10%) developed mild to moderate OHSS. Meanwhile, in Cb group, 4 (13%) patients developed moderate OHSS while two patients (7%) in albumin group developed moderate OHSS. However, a total of 19 patients (63%) developed mild to moderate OHSS in albumin group which was higher than that of Cb with total of 12 patients (39%) with mild to moderate OHSS. The incident of severe OHSS was significantly higher in albumin group compared to Cb and HES group ($P = 0.033$ and $P < 0.001$, respectively). Also, the probability of developing severe OHSS was higher in Cb group than group HES ($P = 0.031$). The differences between the groups were depicted in Figure 1. You should also compare the incident of OHSS in total in the two groups.




Figure 1: Frequency of mild, moderate, and severe ovarian hyperstimulation syndrome in three groups of study. HES: Hydroxyl ethyl starch. a: Difference between cabergoline and albumin groups, $P = 0.033$. b: Difference between albumin and hydroxyl ethyl starch groups, $P < 0.001$. c: Difference between cabergoline and hydroxyl ethyl starch groups, $P = 0.031$

DISCUSSION

OHSS is an iatrogenic complication of ovarian stimulation in assisted reproductive technology (ART). It varies from a cystic enlargement of ovaries in a mild form to life-threatening clinical condition in more severe forms, needing hospitalization, and prompt therapy. Many preventive strategies and suggested such as volume expanding through IV albumin and HES, and GNRH agonists such have be as Cb. The findings from this study suggest that administration of 1000 ml of HES 6% has a higher prophylactic effect compared to administration of IV HA and oral Cb and that administration of one dose HES 6% on the day of ovum pick up is related to a lower risk of developing severe OHSS in infertile patients going through IVF.

To our knowledge, no study has evaluated the risk of developing severe OHSS in the three different groups of patients receiving IV HA, Cb, and HES. Many other studies have previously compared the effect of HA, HES, and Cb with a control group or together with each other. König *et al.* were

Table 1: Baseline characteristics of patients at severe risk of developing OHSS undergoing IVF

Variables	Mean \pm SD or Frequency	P
Age	A: 30.67 ± 3.55 C: 31.94 ± 3.73 H: 31.96 ± 3.21	0.27
Gravidity $\leq 1\%$ ($>1\%$)	A: 96.7 (3.3) C: 87.1 (12.9) H: 93.3 (6.7)	0.27
Parity $\leq 1\%$ ($>1\%$)	A: 100 C: 90.3 (9.7) H: 100	0.07
Death Never % ($\geq 1\%$)	A: 96.7 (3.3) C: 93.5 (6.5) H: 100	0.37
Ectopic pregnancy Never % ($\geq 1\%$)	A: 100 C: 93.5 (6.5) H: 90 (10)	0.22
Abortion Never % ($\geq 1\%$)	A: 93.3 (6.7) C: 93.5 (6.5) H: 96.7 (3.3)	0.82

A = Albumin group; C = Cabergoline group; H = HES group; SD=Standard deviation; OHSS = Ovarian hyperstimulation syndrome; IVF = *In-vitro* fertilization; HES = Hydroxyl ethyl starch

Table 2: Incident OHSS among three groups

Group	OHSS n (%)				P
	Mild	Moderate	Severe	Without OHSS	
Albumin (n=30)	17 (56)*	2 (7)	3 (10)	8 (27)	<0.05
Cabergoline (n=31)	8 (26)	4 (13)	1 (3)	18 (58)	<0.05
HES (n=30)	1 (3)	2 (7)	-	27 (90)	<0.01
Total	26	8	4		

P: Each group versus other two groups. OHSS = Ovarian hyperstimulation syndrome; HES = Hydroxylethyl starch

the first to report a significant reduction in the development of moderate to severe OHSS after use of HES 6%. Of all 51 infertile patients who received a 6% HES solution, only one patient developed moderate OHSS and it significantly differed of that of placebo group with an incident rate of 14% for moderate to severe OHSS.^[18] These finding was in accord with our study that none of the patients in HES group had severe OHSS. Only two patients developed moderate OHSS in HES group, leading the incident rate of 6% for moderate OHSS. In another study, 16 patients with severe OHSS were hospitalized and received either albumin (10 patients) or HES (6 patients) as a colloid solution. The results revealed that 6% HES solution may be even more effective than HA in the treatment of severe OHSS.^[19] However, their sample size was small, and HES was used after OHSS was established, compared to our study in which HES was used as a prophylactic agent on the day of ovum pick up.

Compared to HES and Cb, the incident of severe OHSS was higher among patients who received HA. Also, the incident rate for a mild form of OHSS in patients receiving albumin was significantly higher than HES and Cb. Although some studies have shown the effect of albumin in reducing the incidence of severe OHSS,^[8-11] many recent studies have demonstrated that HA is not a proper intervention in preventing OHSS^[14,19] due to side effects and the possibility of worsening OHSS.^[20]

Different strategies have been suggested for the administration of HES. In this study, we preferred to use the previously suggested dose of 1000 ml 6% HES solution. Gokmen *et al.* used a dose of 500 ml and reported to be as effective as the routine dose of 1000 ml.^[13]

The effect of Cb as a prophylactic therapy for OHSS was studied in several surveys;^[15,16] however, no study compared the effect of Cb and HES. Our results showed that the incident of moderate to severe OHSS was significantly higher in those patients who received Cb than those who were administered HES ($P = 0.031$).

Our results reveal that by administrating 1000 of 6% HES on the day of oocyte retrieval, the incidence of OHSS will be minimized in patients at high risk of developing this clinical condition, compared to administration of Cb and HA.

Our study was the first one to compare the effect of these three strategies on a group of infertile women undergoing ART. Further studies with focusing on drug dosage and timing of administration are highly recommended.

Acknowledgments

The study was approved by Isfahan Ethical Committee of Isfahan University of Medical Sciences (project number: 392298).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

AUTHOR'S CONTRIBUTION

AG and NM were designed the study, NM collected data with NH, final draft were prepared by all authors and submitted to this journal.

REFERENCES

1. Corbett S, Shmorgun D, Claman P; Reproductive Endocrinology Infertility Committee, Healey S, Gysler M. The prevention of ovarian hyperstimulation syndrome. *J Obstet Gynaecol Can* 2014;36:1024-36.
2. Csokmay JM, Yauger BJ, Herne MB, Armstrong AY, Queenan JT, Segars JH. Cost-analysis model of outpatient management of ovarian hyperstimulation syndrome with paracetamol: "Tap early and often" versus hospitalization. *Fertil Steril* 2010;93:167-73.
3. Casals G, Fábregues F, Pavesi M, Arroyo V, Balasch J. Conservative medical treatment of ovarian hyperstimulation syndrome: A single center series and cost analysis study. *Acta Obstet Gynecol Scand* 2013;92:686-91.
4. Mocanu E, Redmond ML, Hennelly B, Collins C, Harrison R. Odds of ovarian hyperstimulation syndrome (OHSS) – Time for reassessment. *Hum Fertil (Camb)* 2007;10:175-81.
5. Balasch J, Arroyo V, Carmona F, Llach J, Jiménez W, Paré JC, *et al.* Severe ovarian hyperstimulation syndrome: Role of peripheral vasodilation. *Fertil Steril* 1991;56:1077-83.
6. Banker M, Garcia-Velasco JA. Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. *J Hum Reprod Sci* 2015;8:13-7.
7. Pala S, Atilgan R, Ozkan ZS, Kavak SB, Ilhan N, Akpolat N, *et al.* Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: An experimental study. *Drug Des Devel Ther* 2015;9:1761-6.
8. Asch RH, Ivery G, Goldsman M, Frederick JL, Stone SC, Balmaceda JP. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. *Hum Reprod* 1993;8:1015-20.
9. Kwan I, Bhattacharya S, Kang A, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). *Cochrane Database Syst Rev* 2014;8:CD005289.
10. Youssef MA, Al-Inany HG, Evers JL, Aboulghar M. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. *Cochrane Database Syst Rev* 2011;16:CD001302.
11. Isik AZ, Gokmen O, Zeyneloglu HB, Kara S, Keles G, Gulekli B. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in *in-vitro* fertilization patients: A prospective, randomized and controlled study. *Eur J Obstet Gynecol Reprod Biol* 1996;70:179-83.
12. Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: Pathophysiology and prevention. *J Assist Reprod Genet* 2010;27:121-8.
13. Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an *in-vitro* fertilization programme: A prospective randomized placebo controlled study. *Eur J Obstet Gynecol Reprod Biol* 2001;96:187-92.

14. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: Guidance for the clinician. *Fertil Steril* 2010;94:389-400.
15. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, *et al.* Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. *J Clin Endocrinol Metab* 2007;92:2931-7.
16. Tehraninejad ES, Hafezi M, Arabipour A, Azimineko E, Chehrizi M, Bahmanabadi A. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: A randomized clinical trial. *J Assist Reprod Genet* 2012; 29:259-64.
17. Golan A, Ron-el R, Herman A, *et al.* Ovarian hyperstimulation syndrome: an update review. *Obstet Gynecol Surv* 1989;44:430-40.
18. König E, Bussen S, Sütterlin M, Steck T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in *in-vitro* fertilization patients: A prospective, randomized, double-blind and placebo-controlled study. *Hum Reprod* 1998;13:2421-4.
19. Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: A preliminary report. *Fertil Steril* 2001;75:1228-30.
20. Ndukwe G, Thornton S, Fishel S, Dowell K, Aloum M. Severe ovarian hyperstimulation syndrome: Is it really preventable by prophylactic intravenous albumin? *Fertil Steril* 1997;68:851-4.

Archive of SID